Drug Discovery

Mersana, Janssen Biotech partner to discover new ADC product candidates

Mersana Therapeutics and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a research collaboration and license agreement for the discovery of new antibody-drug conjugates (ADCs) for three targets.

Alvotech, BiosanaPharma partner to develop biosimilar for Xolair

Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).

Ocugen to buy Liminal’s vaccine manufacturing facility in Canada

US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.

Twist Bioscience, Artisan Development Labs partner to discover cell therapies

Twist Bioscience has teamed up with Artisan Development Labs to discover new antibodies against five undisclosed targets.

Prellis, Bristol Myers Squibb collaborate to discover antibodies

Prellis Biologics and Bristol Myers Squibb have signed a multi-target collaboration and license agreement to discover antibodies.

Lantern Pharma and NCI expand oncology partnership

Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced the extension of their oncology collaboration for first in human clinical trials for drug candidates LP-184 and LP-284.

Absci and Merck collaborate to develop new enzymes

Drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.

Amgen, Generate Biomedicines partner to create protein therapeutics

Amgen has entered into a research collaboration agreement with Generate Biomedicines to discover and create protein therapeutics for five clinical targets across several modalities.

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.